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Abstract
Introduction This prospective randomized clinical study
investigated the efficacy and safety of 7.2% hypertonic saline
hydroxyethyl starch 200/0.5 (7.2% NaCl/HES 200/0.5) in
comparison with 15% mannitol in the treatment of increased
intracranial pressure (ICP).
Methods Forty neurosurgical patients at risk of increased ICP
were randomized to receive either 7.2% NaCl/HES 200/0.5 or
15% mannitol at a defined infusion rate, which was stopped
when ICP was < 15 mmHg.
Results Of the 40 patients, 17 patients received 7.2% NaCl/
HES 200/0.5 and 15 received mannitol 15%. In eight patients,
ICP did not exceed 20 mmHg so treatment was not necessary.
Both drugs decreased ICP below 15 mmHg (p < 0.0001); 7.2%
NaCl/HES 200/0.5 within 6.0 (1.2–15.0) min (all results are
presented as median (minimum-maximum range)) and mannitol
within 8.7 (4.2–19.9) min (p < 0.0002). 7.2% NaCl/HES 200/
0.5 caused a greater decrease in ICP than mannitol (57% vs
48%; p < 0.01). The cerebral perfusion pressure was increased
from 60 (39–78) mmHg to 72 (54–85) mmHg by infusion with
7.2% NaCl/HES 200/0.5 (p < 0.0001) and from 61 (47–71)
mmHg to 70 (50–79) mmHg with mannitol (p < 0.0001). The
mean arterial pressure was increased by 3.7% during the
infusion of 7.2% NaCl/HES 200/0.5 but was not altered by
mannitol. There were no clinically relevant effects on electrolyte
concentrations and osmolarity in the blood. The mean effective
dose to achieve an ICP below 15 mmHg was 1.4 (0.3–3.1) ml/
kg for 7.2% NaCl/HES 200/0.5 and 1.8 (0.45–6.5) ml/kg for
mannitol (p < 0.05).
Conclusion 7.2% NaCl/HES 200/0.5 is more effective than
mannitol 15% in the treatment of increased ICP. A dose of 1.4
ml/kg of 7.2% NaCl/HES 200/0.5 can be recommended as
effective and safe. The advantage of 7.2% NaCl/HES 200/0.5
might be explained by local osmotic effects, because there were
no clinically relevant differences in hemodynamic clinical
chemistry parameters.
Introduction
The development or presence of secondary brain injury in
patients with intracranial pathology has been associated with
increased morbidity and mortality. An increase in intracranial
pressure (ICP) accompanied by a low cerebral perfusion pres-
sure (CPP) should therefore be avoided in these patients.R530
BBB = blood-brain barrier; CPP = cerebral perfusion pressure; GCS = Glasgow Coma Score; ICH = intracerebral hemorrhage; ICU = intensive care 
unit; SAH = subarachnoid hemorrhage; SAPS = simplified acute physiology score; SHT = severe head trauma; SpO2 = peripheral oxygen saturation
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R531Several clinical studies have demonstrated that outcome is
improved by adequate pharmacological or neurosurgical treat-
ment optimizing ICP [1-3]. According to established treatment
guidelines, an ICP >20 mmHg and a CPP <60 mmHg are
considered critical [4-8]. Early recognition of such critical epi-
sodes by multimodal neuromonitoring, and selection of an
effective and safe drug for treatment are essential for
neuroprotection.
Osmotherapy has been used since the early 20th century to
treat increased ICP. The physiological basis and concept of
osmotherapy was first published in 1919 [9]. Intravenous infu-
sion of mannitol is considered to be the 'gold standard' for the
treatment of increased ICP. Barbiturates and TRIS buffer are
still used as alternative treatments, although their use in clinical
practice is limited by cardiovascular and metabolic side effects
[10-13]. In addition, experimental and clinical evidence has
shown that 'small volume resuscitation' has a positive effect in
the treatment of increased ICP in trauma patients [14-16].
Experimentally, intravenous application of hypertonic saline
increases global cerebral perfusion as well as the right-shifted
oxygen dissociation curve, both with consecutive improve-
ment of oxygen delivery. At the same time, an increase of cer-
ebral compliance and decrease in ICP occur by decrease of
the brain edema [17].
Although several experimental and clinical studies have inves-
tigated the effects of hypertonic saline or mannitol on ICP, only
a few studies comparing these drugs in neurosurgical patients
have been published [18-22]. Furthermore, there are no clini-
cal data available for recommendation of an 'effective dose' of
hypertonic saline in clinical practice.
The purpose of this study was to compare the efficacy and
safety of 7.2% NaCl/HES 200/0.5 and mannitol 15% in neu-
rosurgical patients with increased ICP. This study focuses on
the effects of both drugs on ICP, CPP, mean arterial pressure
(MAP), hematocrit, serum sodium and osmolarity. Further-
more, we attempted to recommend an effective dose for the
application of hypertonic saline.
Methods
After approval by the local ethics committee and written
informed consent being obtained from the patients' legal rela-
tives, neurosurgical patients with severe neuronal damage
(e.g. cerebral trauma, spontaneous intracerebral bleeding or
subarachnoidal bleeding) were enrolled in this prospective
randomized study. The patients were randomized to receive
either 7.2% NaCl/HES 200/0.5 (HyperHAES®, Fresenius
Kabi Deutschland GmbH, Bad Homburg) or mannitol (Osmo-
fundin® 15%-N, B. Braun Melsungen AG, Melsungen, Ger-
many), to treat increased ICP.
Inclusion criteria were: age >18 years, severe brain damage
(Glasgow Coma Score <8) with cerebral edema – visualized
by CT scan and continuous monitoring of ICP. Exclusion crite-
ria were: elevated ICP due to space-occupying lesions with
indication for neurosurgical intervention (e.g. bleeding, hydro-
cephalus), severe renal failure, metabolic disorders, initial
serum sodium >150 mmol/l and initial serum osmolarity >320
mosm/kg.
Standard treatment protocol
All patients were intubated and received pressure-controlled
mechanical ventilation (Bilevel Positive Airway Pressure
(BiPAP), etCO2 4.2–4.8 kPa, FiO2 0.3–1.0). Care was taken
to keep the arterial partial oxygen pressure above 15 kPa, the
hemoglobin concentration above 5.5 mmol/l and the CPP
above 70 mmHg. If necessary, blood pressure was supported
with vasopressor therapy. Blood glucose was adjusted to val-
ues between 6–8 mmol/l by continuous application of human
insulin. Patients' core temperature was measured via the blad-
der, with a target temperature of 36.0–37.0°C. If the core tem-
perature exceeded 37.0°C, external cooling blankets were
used to cool the patient, otherwise patients were covered
either with an additional blanket or with an active heating blan-
ket (Bair Hugger; Augustine Medical, Eden Prairie, MN, USA).
Analgosedation and continuous patient monitoring were man-
aged according to the standards of the Department of
Anesthesiology and Critical Care at the Martin-Luther-Univer-
sity Halle-Wittenberg, Germany. Analgosedation at days 1–4
was performed using propofol and sufentanil or remifentanil.
Thereafter, midazolam and sufentanil were administered. The
standard monitoring included electrocardiogram, invasive
arterial blood pressure, central venous pressure, peripheral
oxygen saturation (SpO2) and intraparenchymal ICP measure-
ment (Codman Microsensor ICP Monitoring System; Codman
& Shurtleff Inc, Raynham, MA, USA).
An increase in ICP was treated first by deepening the sedation
and analgesia by titrating the medication and adjusting to ade-
quate ventilator settings. If ICP exceeded the 20 mmHg
threshold for more than 5 min, the study medication (mannitol
or 7.2% NaCl/HES 200/0.5 (herein referred to as '7.2%
hypertonic saline' or 'hypertonic saline') was infused via the
central venous line using an automated infusion system at a
defined infusion rate. The infusion was stopped when ICP was
reduced to <15 mmHg, defined as the treatment goal. How-
ever, in the case of sustained ICP problems (ICP >15 mmHg
or CPP <70 mmHg) after these measures, bolus applications
of thiopentone (maximum single bolus: 5 mg/kg) were allowed.
In these patients, the possibility of a space-occupying lesion
was excluded by CT scan.
Data acquisition and statistical analysis
Mean arterial blood pressure, heart rate, SpO2, ICP and calcu-
lated CPP were continuously measured. Analysis of these
Available online http://ccforum.com/content/9/5/R530
R532parameters was performed at the following time points: initia-
tion of infusion; after termination of infusion (ICP <15 mmHg
achieved); 10 min after terminating infusion; 30 min after ter-
minating infusion; and 60 min after terminating infusion. Serum
sodium level and hematocrit were measured every 4 h and the
serum osmolarity every 12 h. The values taken before the ther-
apy, as well as the maximum values subsequently achieved,
were analyzed. Individual outcomes were assessed at the end
of stay in the intensive care unit (ICU) using the differentiation
between survivors and non-survivors.
The random code for group assignment was generated by
computer. The software package Stat View 4.0 (Abacus Con-
cepts Inc, Berkeley, CA, USA) was used for all statistical cal-
culations. All demographic data are presented as mean ± SD.
The clinical values in both groups were not normally distrib-
uted. Results are presented as median (minimum-maximum
range). Groups were compared using the non-parametric
Mann-Whitney U-Test and the Wilcoxon Signed Rank was
employed to analyze the effect of the medication used within
each group; p < 0.05 was regarded as statistically significant
and computed significance levels are given.
Results
A total of 40 neurosurgical patients were recruited according
to the inclusion criteria and randomized to receive either 7.2%
NaCl/HES 200/0.5 (n = 17) or mannitol 15% (n = 15) to treat
increased ICP. Only 32 patients were evaluated since in eight
patients, ICP did not exceed 20 mmHg, therefore no study
medication was administered.
Demographic data of all analyzed patients are summarized in
Table 1. There were no significant differences between the
two groups. No relevant clinical characteristics were revealed
in the eight patients not undergoing osmotic therapy.
Analgosedation was started in all patients using our standard
protocol. In four patients in the 7.2% hypertonic saline group
and five patients in the mannitol group, propofol was substi-
tuted by thiopental because of sustained ICP problems.
Heart rate and blood pressure
The average baseline heart rate was 78 (58–95) bpm in the
mannitol and 76 (52–92) bpm in the hypertonic saline group
(p = NS). The infusion of study medication produced no clini-
cally relevant changes in heart rate and no arrhythmias.
The initial MAP was 84 (68–92) mmHg in the mannitol group
and 82 (64–98) mmHg in the hypertonic saline group (p =
NS). Maximal changes could be analyzed in the mannitol group
after 10 min (83 (69–105) mmHg) and in patients receiving
hypertonic saline after 30 min (85 (74–98) mmHg) (Fig. 1,
Table 2).
The individual maximum increase of MAP during the observa-
tion time after infusion of mannitol was 5.8% to 88 (72–106)
mmHg and after infusion of hypertonic saline was 7.6% to 85
(74–98) mmHg. The time of the maximal increase was individ-
ual for each patient as well.
Table 1
Demographic data of analyzed patients
Mannitol 15% (n = 15) 7.2% NaCl/HES 200/0.5 (n = 17)
Age 47 ± 16 47 ± 16
Weight 89 ± 27 87 ± 24
Gender, M/F 8/7 9/8
Initial GCS 5.8 ± 1.4 6 ± 1.3
SAPS score 42.5 ± 13 39.6 ± 9.6
Days on ICU 23.3 ± 14.8 22.8 ± 15.5
Basic illness
SAH 5 4
Brain infarct 4 3
Isolated SHT III° 4 6
ICH 1 3
Other 1 1
Surgical intervention 13 13
7.2% NaCl/HES 200/0.5, 7.2% hypertonic saline hydroxyethyl starch 200/0.5; GCS, Glasgow Coma Score; ICH, intracerebral hemorrhage; ICU, 
intensive care unit; SAPS, simplified acute physiology score; SHT, severe head trauma.
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Prior to administration of the study medication, the mean ICP
was 23 (19–30) mmHg in the mannitol group and 22 (19–31)
mmHg in the hypertonic saline group (p = NS). After infusion
with mannitol, the ICP decreased to 14 (7–20) mmHg and
after infusion with hypertonic saline it decreased to 15 (8–18)
mmHg (p < 0.0001). This effect was achieved within 8.7 (4.2–
19.9) min by mannitol and 6.0 (1.2–15.0) min by hypertonic
saline (p < 0.0002) and maintained over the 1 h observation
period. The lowest ICP was 12 (6–19) mmHg in the mannitol
and 10 (6–14) mmHg in the hypertonic saline group (p <
0.05), observed 30 min after the end of infusion. Thus, the
maximum decrease in ICP produced by hypertonic saline was
57% and that of mannitol 48%. Sixty minutes after the end of
infusion, the ICP in the hypertonic saline group was still lower
than that of the mannitol group (11 (5–18) mmHg; vs 14 (7–
20) mmHg; p < 0.005) (Fig. 2, Table 2).
Prior to administration of study medication, the mean CPP was
61 (47–71) mmHg in the mannitol and 60 (39–78) mmHg in
the hypertonic saline group (p = NS; Fig. 3). At the end of infu-
sion, a significant increase of CPP to 70 (50–79) mmHg after
mannitol infusion (p < 0.0001) and 72 (54–85) mmHg after
hypertonic saline infusion (p < 0.0001) occurred. This
improvement was maintained during the whole study period.
The maximal increase in CPP occurred in both groups after 30
min (mannitol +18%; hypertonic saline +27%; p < 0.05). CPP
was significantly higher in the hypertonic saline group (p <
0.01, Fig. 3, Table 2) 30 and 60 min after the end of infusion.
The 15 patients in the mannitol group had a total of 53 epi-
sodes of increased ICP exceeding 20 mmHg requiring infu-
sion of study medication (3.5 treatments/patient). For 49 of
these episodes (92.5%), infusion of mannitol was effective
and reduced ICP to <15 mmHg within 8.7 (4.2–19.9) min. For
one episode, mannitol produced a delayed effect, appearing
20 min after application of a total of 235 ml mannitol (2.6 ml/
kg). In three episodes, however, ICP could not be reduced
below 15 mmHg by an infusion of up to 2.1 ml/kg of mannitol.
In two of these patients, thiopental was given intravenously at
up to 3 mg/kg and in one patient a unilateral decompressive
craniectomy was performed.
In the 17 patients in the hypertonic saline group, 57 periods of
increased ICP occurred (3.3 treatments/patient). 7.2% NaCl/
HES 200/0.5 was effective in 55 episodes (96.5%), reducing
ICP to <15 mmHg within 6.0 (1.2–15.0) min. In one episode,
hypertonic saline (3 ml/kg) was only effective after an addi-
tional bolus of thiopental 3 mg/kg was given and, in another
episode, ICP could not be reduced below 15 mmHg by an
infusion of up to 3.1 ml/kg of hypertonic saline. Finally, mild
hyperventilation (etCO2 ~28–30 mmHg) achieved the target
ICP value <15 mmHg.
Table 2
Time course of heart rate, MAP, ICP and the CPP for the two different treatment groups
Start infusion Terminating infusion +10 min +30 min +60 min
Heart rate, l/min
7.2% NaCl/HES 200/0.5 76 [52–92] 78 [60–104] 77 [62–107] 78 [62–101] 79 [61–99]
Mannitol 15% 78 [58–95] 80 [58–96] 80 [60–95] 81 [58–93] 79 [56–96]
MAP, mmHg
7.2% NaCl/HES 200/0.5 84 [64–98] 84* [68–96] 84* [67–97] 85* [74–100] 84 [63–94]
Mannitol 15% 84 [68–92] 85 [65–98] 83 [69–105] 81 [69–106] 82 [68–108]
ICP, mmHg
7.2% NaCl/HES 200/0.5 22 [19–31] 15** [8–18] 12** [2–16] 10**,++ [6–14] 11**,+ [5–18]
Mannitol 15% 23 [19–30] 14** [7–20] 13** [4–19] 12** [6–19] 14** [7–20]
CPP, mmHg
7.2% NaCl/HES 200/0.5 60 [39–78] 72** [54–85] 72** [55–89] 75**, #[62–86] 73**, #[58–88]
Mannitol 15% 61 [47–71] 70** [50–79] 70** [56–92] 72** [60–93] 69** [56–89]
*p < 0.05, **p < 0.0001 compared with start infusion. +p < 0.0001, ++p < 0.01, #p < 0.05 between treatment regimes. HR, heart rate; CPP, 
cerebral perfusion pressure; ICP, intracranial pressure; MAP, mean arterial pressure.
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1.8 (0.45–6.5) ml/kg) required to reduce ICP below 15 mmHg
was significantly higher than that of hypertonic saline (100
(35–250) ml/application; 1.4 (0.3–3.1) ml/kg). Repeated
administration of mannitol caused an increase of the required
single dose in six out of 15 patients (40%) and a decrease in
two patients (13%). Repeated administration of hypertonic
saline caused an increase of the required single dose in two
patients (12%) and a decrease in seven patients (41%).
Clinical chemistry
Hematocrit was not significantly changed by infusion of man-
nitol (0.3 (0.27–0.42) vs 0.29 (0.26–0.40)) and hypertonic
saline (0.29 (0.24–0.37) vs 0.29 (0.24–0.36)). A temporary,
but statistically significant increase of serum sodium occurred
after infusion of the hypertonic saline from 143 (136–148)
mmol/l to 148 (144–153) mmol/l (p < 0.001). Serum osmolar-
ity increased significantly after infusion of hypertonic saline:
284 (273–300) mosm/kg to 300 (284–319) mosm/kg (p <
0.001), as well as after infusion of mannitol: 286 (270–315)
mosm/kg to 295 (278–327) mosm/kg (p < 0.001).
Outcome
Ten patients (58.8%) assigned to the group receiving hyper-
tonic saline survived, the remaining seven patients died
(41.2%). In the group with the mannitol treatment, six patients
survived (40.0%) and nine patients died (60.0%). The chi-
square test revealed no statistical significance.
In patients who survived, a lower dose of the osmotic agent
had been administered. Survivors in the hypertonic saline
group received a significant lower dose of 1.4 (0.32–2.8) ml/
kg hypertonic saline. In non-survivors, the dosage given was
1.7 (0.9–3.1) ml/kg (p < 0.05). In the mannitol group, patients
who survived received 1.7 (0.5–3.4) ml/kg mannitol versus 1.9
(1.0–6.5) ml/kg mannitol in patients who died (p = NS). There-
fore, a statistical significance regarding the influence of the
specific osmolarity, either of hypertonic saline or mannitol,
given with each treatment, on changes of the cerebral hemo-
dynamics (ICP, CPP) or patients' individual outcomes could
not be analyzed.
Discussion
The strong relationship between incidence of increased ICP
and outcome in patients with neuronal damage emphasizes
the vulnerability of the injured brain and the need for adequate
Figure 1
Box-and-whisker plots of the MAP. Data are plotted for the first hour after administration of 7.2% NaCl/HES 200/0.5 (HS) or mannitol 15% (M). In 
patients receiving 7.2% NaCl/HES 200/0.5, the MAP change was statistically significant compared with the value at the start of treatment († p < 
0.05). The changes with mannitol were not statistically significant within the group, but significant after 30 min to HS (*p < 0.05). MAP, mean arterial 
pressure.
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patients has changed over recent decades, especially regard-
ing the introduction and acceptance of clinical guidelines
among neurosurgeons and intensivists [4,10,23,24]. It has
become a generally accepted treatment goal to keep the CPP
above 70 mmHg, because episodes of CPP <60 mmHg or
ICP >20 mmHg are associated with a worse outcome [6-8].
These goals are incorporated into current treatment protocols,
which are constantly analyzed with regards to their efficacy
and feasibility, and updated accordingly. Osmotic agents are
important components of all treatment protocols, especially
mannitol as it is a well-established treatment for increased ICP
following brain injury. Surveys of the critical care management
of head-injured patients show that 83% of the centers in the
United States and 100% of the centers in the United Kingdom
used mannitol to control ICP [25-27]. The clinical use of man-
nitol is, however, limited by renal complications and the fast
increase of the osmotic gradient followed by its reversal due
to disruption of the blood-brain barrier (BBB) [28-31]. Further-
more, mannitol (at concentrations which may be reached in
clinical conditions) and the hyperosmotic stress itself can acti-
vate the process of apoptotic cell death [32].
Recent data have demonstrated different osmotic effects of
mannitol. Videen and co-workers [33] observed that after
administration of 1.5 g/kg bolus of mannitol in six patients with
acute complete middle cerebral artery infarctions, the brain in
the non-infarcted hemisphere shrank more than in the inf-
arcted hemisphere. This may increase the inter-hemispheric
pressure difference and worsen tissue shift [33].
Hypertonic saline is an interesting alternative to mannitol,
because there is experimental and clinical evidence that it can
reduce ICP and improve CPP [34-39]. Experimental studies in
animals suffering from a combination of hemorrhagic shock
and head trauma demonstrated a significant reduction of ICP,
an improvement of CPP and/or a reduction of brain edema
[34-36,40,41].
The efficacy of hypertonic saline after isolated brain injury,
however, has rarely been investigated. Qureshi et al. [22]
examined different concentrations of hypertonic saline
(23.4%, 3.0%) versus mannitol after isolated experimental
intracerebral hemorrhage in a canine model. The acute effects
on ICP and CPP were most prominent after infusion of hyper-
tonic saline 23.4%, but were better sustained after infusion of
Figure 2
Box-and-whisker plots of the ICP. Data are plotted for the first hour after intravenous administration of 7.2% NaCl/HES 200/0.5 (HS) or mannitol 
(M). The ICP decreases after injection of the respective test substance significantly in comparison with the baseline value at the start of treatment († 
p < 0.0001). After 30 min and 60 min, a statistically significant difference was seen between the two treatment regimes (p < 0.05) ICP, intracranial 
pressure.
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mannitol infusion in most regions of the brain, especially in the
white matter ipsilateral to the hematoma. The authors specu-
lated that these results were due to a certain permeability of
the BBB. The most positive effect on water content was seen
after hypertonic saline 3% [22].
Berger et al. [42] compared the efficacy of hypertonic saline
and mannitol to reduce ICP after a combination of two differ-
ent neuronal injuries. Initially, a cold-induced focal lesion was
used to induce a vasogenic brain edema in rabbits, then intrac-
ranial hypertension was induced by a further inflation of an epi-
dural balloon. The authors demonstrated that hypertonic
solution as well as mannitol can reduce the ICP efficiently.
After the first application, the effect of mannitol was enhanced
compared with the hypertonic solution (98 ± 14 min vs 189 ±
27 min; p < 0.054), but became the same after repeated appli-
cations. It is remarkable that mannitol was more effective in
decreasing the water content in brain tissue in the traumatized
hemisphere, whereas hypertonic solution lowered the water
content in the contralateral brain tissue. An accumulation of
mannitol could occur, followed by a possible reversal of the
local osmotic gradient. These different effects on brain tissue
could be an explanation for the failed therapeutic efficiency
after mannitol and emphasized the advantages of hypertonic
solutions [42]. Furthermore, Prough et al. observed a higher
regional cerebral blood flow in dogs with induced intracerebral
hemorrhage after hypertonic saline without any increase of the
CPP [43].
The positive effect of 7.2% hypertonic saline on ICP has also
been demonstrated in several clinical studies investigating
patients with therapy-refractory ICP increase due to isolated
brain injury but without hemorrhagic shock [21,44-46]. Hyper-
tonic saline had no effects on MAP in these euvolaemic
patients [46].
Schwarz et al. [47] evaluated the efficacy of hypertonic saline
hydroxyethyl starch 7.55% in comparison with mannitol 20%
in stroke patients with increased ICP. Hypertonic saline
hydroxyethyl starch was effective in all, mannitol in only 70% of
patients. The maximum ICP decrease was seen 25 min after
the start of hypertonic saline infusion and 45 min after the start
of mannitol infusion. There was no constant effect on CPP in
the hypertonic saline group, whereas CPP rose significantly in
the mannitol-treated group. The authors concluded that hyper-
tonic saline hydroxyethyl starch seems to lower ICP more
Figure 3
Box-and-whisker plots of the mean CPP. Data are plotted within the first hour after administration of 7.2% NaCl/HES 200/0.5 (HS) or mannitol (M). 
The CPP increases significantly compared with the start of treatment († p < 0.0001). After 30 min and 60 min, a statistically significant difference 
was seen between the two treatment regimes (p < 0.01). CPP, cerebral perfusion pressure.
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[47].
Hypertonic saline has also been used to reduce ICP in
patients with brain tumors or subarachnoid hemorrhage. Sua-
rez et al. [48] reported a significant decrease of ICP and
increase of CPP in these patients, when application of manni-
tol had been previously unsuccessful. Similar results were
observed by Horn et al. in patients with traumatic brain injury
and subarachnoidal hemorrhage, where hypertonic saline
7.5% adequately reduced ICP after mannitol therapy had
failed [44].
Based on these findings, patients with isolated head trauma
can also be expected to benefit from hypertonic saline. This
patient population covers some specific patho-physiological
conditions, characterized by diffuse axonal injuries, hemor-
rhages, and necrotic and edematous tissue, which can lead to
different therapeutic strategies and a failed positive effect of
hypertonic saline compared with patients with other intracra-
nial mass lesions [49,50]. Munar et al. [51] investigated the
acute effects of 7.2% hypertonic saline on ICP, cerebral blood
flow and systemic hemodynamics in patients with moderate
and severe traumatic brain injury during the first 72 h after
injury. Hypertonic saline significantly reduces ICP without
changes in MAP and relative global cerebral blood flow,
expressed as 1/AVDO2. These results suggest that hypertonic
saline decreases ICP by means of an osmotic mechanism
[51].
Not all studies, however, reported positive effects of hyper-
tonic saline on ICP, especially if hypertonic saline was infused
continuously. Qureshi et al. analyzed the effect of continuous
administration of hypertonic saline 2% or 3% in patients with
head trauma. They reported a higher in-hospital mortality rate
in patients receiving hypertonic solutions and described no
favorable impact on the rate of necessary medical interven-
tions during the patient's treatment in the ICU. The influence
of hypertonic saline on the supposedly disrupted BBB after
head injury was mainly used to explain the failed effect. A dis-
rupted BBB can lead to an accumulation of sodium resulting
in an reversal of the osmotic gradient with concomitant
increase of ICP [52]. However, Hartl et al. demonstrated a
reduced water content in areas with a disturbed BBB in a
model with or without a focal cryogenic brain lesion and hem-
orrhagic shock [53].
Our results showed that bolus application of either study med-
ication, mannitol 15% or hypertonic saline 7.2%, significantly
decreases ICP and increases CPP (Table 2). The effect of
hypertonic saline on ICP was significantly better than that of
mannitol. Clinically important effects of both drugs on MAP
could not be determined, although some statistically signifi-
cant differences were observed at a few measurement points.
Therefore, it can be concluded that local cerebral dehydration
is the main mechanism of both substances in decreasing ICP
and optimizing CPP. The higher potency of hypertonic saline
suggests that its local effect is more clearly pronounced.
However, the mechanisms whereby hypertonic solutions
reduce ICP are multifactorial and are still discussed with some
controversy. The main principle seems to be the 'local dehy-
dration' of brain tissue drawing water from parenchyma to the
intravascular space following an osmotic gradient [54]. Com-
paring this with the osmotic effect of mannitol, a second mech-
anism to explain the effect of the ICP-reduction must exist. This
hypothesis is supported by the results of Berger et al. [42]. He
found, in rats with induced head injury, a similar positive effect
on ICP with regards to the amount and duration of the
decrease, but a higher CPP in the rats receiving mannitol.
Contrary to our results, the MAP increased after hypertonic
saline, whereas the MAP temporarily decreased after mannitol.
The authors hypothesized that the different effects of the two
solutions are the result of a selective permeability of the BBB
and/or the different reflection coefficients. A disrupted BBB
would have to be the result of an accumulation of both solu-
tions in the brain tissue. Therefore different mechanisms of
local cerebral dehydration must exist [42]. These hypotheses
are supported by the results of Worthley et al. and Kaufmann
et al. Both working groups demonstrated that the ICP-
decreasing effect is limited after repeated bolus applications
of mannitol, but a further application of hypertonic saline lead
to a further ICP reduction [55,56]. However, a direct vasodila-
tation of pial vessels [57-59], the reduction of blood viscosity
due to enhancement of the intravascular volume, the rapid
absorption of cerebrospinal fluid and restoration of the normal
membrane potentials are other effects to positively affect the
ICP [60,61]. Our results only support the hypothesis about the
local dehydration of brain tissue. Systemic hemodynamic
effects for the given dosage couldn't be demonstrated, but the
decreased ICP leads to the improved CPP. All homeostatic
side effects after hypertonic saline, for instance hypernatriemia
and increased serum osmolarity, are temporary and without
systemic hemodynamic side effects. Such complications as
described in the literature, emphasize cardiac failure with lung
edema, metabolic acidosis, coagulopathia subdural
hematoma and central pontine myolysis as the most important
[22,40,48]. With the intention of limiting the side effects of
changes in electrolytes and osmolarity, a standardized labora-
tory measurement procedure is needed.
The substantial difference in the design of the present and a
comparable study is the fact that we did not administer a fixed
total dose, but infused the study medication at a defined infu-
sion rate until ICP decreased to <15 mmHg, the primary goal
of our treatment. No clinical study has so far identified an exact
dose-effect relationship for hypertonic saline. Only one com-
parable clinical study confirms the superiority of 2.0 ml/kg of
hypertonic saline 7.5% over mannitol 20% in head-injured
patients [21]. This study concluded that 2 ml/kg of 7.2%
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dose to reduce increased ICP [21]. In our study, an average
dose of 1.5 ± 0.6 ml/kg of hypertonic saline adequately
reduced ICP below 15 mmHg. Furthermore, because of our
application mode with an defined application rate and a target
ICP of <15 mmHg we could demonstrate a failed influence of
the osmotic load given with each treatment.
Regardless of all positive effects in our study, there are some
limitations that need to be discussed, most of all, the small
patient population of each group and the heterogeneity in the
underlying neurological illness. The primary intention of our
study was pragmatic and adjusted on the typical clinical
routine. However, we included neurosurgical patients with
severe neuronal damage independent from the individual
pathogenesis. To compensate for this to a certain degree, we
used a randomized study design. Furthermore, until now there
have been only limited data available for comparison of these
two osmotic agents in a clinical setting. A small amount of evi-
dence is available that hypertonic saline has some advantages
compared with mannitol in the treatment of patients with
intracranial hypertension after trauma, subarachnoid bleeding
or stroke [21,47,62,63].
Conclusion
7.2% NaCl/HES 200/0.5 and mannitol 15% are effective and
safe drugs in the treatment of increased ICP, although 7.2%
NaCl/HES 200/0.5 is more effective than mannitol. A dose of
1.4 ml/kg can be recommended as an initial dose. The advan-
tage of hypertonic saline can be explained by individual local
osmotic effects, because no relevant systemic changes occur.
The observed effects on electrolytes and plasma osmolarity
are not significantly different between the two osmotic drugs
and have no clinical relevance here. Further experimental and
clinical research is required to evaluate the optimal administra-
tion regime, the best treatment strategies adapted to the indi-
vidual patient's needs and the impact on patients' morbidity
and mortality.
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